StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)

Close on Nov 17, 2026Market cap $4.82BP/E –Yield –

Earnings

Travere Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 18, 2027
Q4 FY2027 · estimated, after the close
Revenue, Q3 FY2027
$224.56M
+36.2% on a year earlier
non-GAAP adjusted net loss per basic share, Q3 FY2027
-$0.31
$0.59 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Travere Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2027ended Dec 31, 2026Feb 18, 2027Expected–––––
Q3 FY2027ended Sep 30, 2026Nov 2, 2026after the close$224.56M+36.2%-$0.55-$0.31Release
Q2 FY2027ended Jun 30, 2026Aug 4, 2026after the close$169.58M+48.2%-$0.37-$0.10Release
Q1 FY2027ended Mar 31, 2026May 4, 2026after the close$127.20M+55.6%-$0.40$0.05Release
Q4 FY2026ended Dec 31, 2025Feb 19, 2026after the close$129.69M+73.4%$0.03$0.37Release
Q3 FY2026ended Sep 30, 2025Oct 30, 2025after the close$164.90M+162.2%$0.28$0.59Release
Q2 FY2026ended Jun 30, 2025Aug 6, 2025after the close$114.40M+111.5%-$0.14$0.13Release
Q1 FY2026ended Mar 31, 2025May 1, 2025after the close$81.73M+97.5%-$0.47-$0.19Release
Q4 FY2025ended Dec 31, 2024Feb 20, 2025after the close$74.79M+66.0%-$0.73-$0.47Release
Q3 FY2025ended Sep 30, 2024Oct 31, 2024before the open$62.90M+69.6%-$0.70-$0.46Release
Q2 FY2025ended Jun 30, 2024Aug 1, 2024after the close$54.10M-9.4%-$0.91-$0.65Release
Q1 FY2025ended Mar 31, 2024May 6, 2024after the close$41.37M-27.4%-$1.76-$1.51Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Travere Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Travere Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Travere Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. News
  4. News
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. News
  14. News
  15. Results

See a number that looks wrong?